about
Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expressionAnti-Hemagglutinin Antibody Derived Lead Peptides for Inhibitors of Influenza Virus BindingVirus-host interactomics: new insights and opportunities for antiviral drug discoveryCombination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In VitroParallel evolution of influenza across multiple spatiotemporal scales.Quantitative influenza follow-up testing (QIFT)--a novel biomarker for the monitoring of disease activity at the point-of-care.Detection of Rare Drug Resistance Mutations by Digital PCR in a Human Influenza A Virus Model System and Clinical Samples.N-acylhydrazone inhibitors of influenza virus PA endonuclease with versatile metal binding modes.At the centre: influenza A virus ribonucleoproteins.Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease.Molecular basis of influenza hemagglutinin inhibition with an entry-blocker peptide by computational docking and mass spectrometry.Potential of acylated peptides to target the influenza A virus.FPR2: A Novel Promising Target for the Treatment of Influenza.Emodin Inhibition of Influenza A Virus Replication and Influenza Viral Pneumonia via the Nrf2, TLR4, p38/JNK and NF-kappaB Pathways.Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein.High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries.In vitro and in vivo effects of Peganum harmala L. seeds extract against influenza A virus.Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein.Novel Platforms for the Development of a Universal Influenza Vaccine.Within-Host Evolution of Human Influenza Virus.Mathematical Analysis of Influenza A Dynamics in the Emergence of Drug Resistance
P2860
Q28543242-C85DAA97-38D7-4671-A69B-C1B7E930D344Q28552622-56535CAC-C3A2-49DA-953B-0B422A30B6DAQ28652236-2F9DEB01-A243-48ED-9B78-3FEBFA2241B0Q30364319-66510941-2B98-4E68-BD57-B4FE5B420F6AQ30390167-76D2399C-F901-4235-B730-BA184981B1A0Q33842490-3E480446-FA59-46B4-A397-F85534DCDDB8Q35128031-5C6DE604-8D69-4A2B-BCD5-74F411DA0F9FQ36521356-64400D7A-6B38-408D-9F23-1B05D7BAC372Q37166751-44767C88-55CD-4831-B158-6E544575401FQ38270617-CF1BD891-4AB6-4762-9340-438F2F48B68CQ38839349-44100BCC-AAE5-4E77-9EF6-5FFFF3378D42Q40982127-AA25EBA7-5AC8-418F-96F0-D24350426ECEQ41131573-E6313C81-EAE0-4C06-A887-5CEC2596AE27Q41450597-3AEE5BFC-1526-4302-B2F4-CE4134C4A3ACQ45070723-3A99A66C-4908-4FBE-8C35-0251F5C342D3Q45323947-EF9805E7-3AF4-4DFE-A318-55115ACB032EQ45325444-147211BF-5B49-4C75-A914-6B3C2A8FEE46Q47102383-FDEEEB78-1A27-4952-B17E-83B28DB81384Q47264095-DC03D21B-0AC7-49C8-91F6-C59FC4C1EC97Q52599675-4211B871-2F0A-44CE-8A27-3E0853D0A90BQ54256631-41DC9084-DBDF-465F-B0F6-99207FA6A59DQ58693316-FCB3F308-0CF0-4050-B3A1-534A1E45F9D8
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Influenza virus resistance to antiviral therapy.
@ast
Influenza virus resistance to antiviral therapy.
@en
type
label
Influenza virus resistance to antiviral therapy.
@ast
Influenza virus resistance to antiviral therapy.
@en
prefLabel
Influenza virus resistance to antiviral therapy.
@ast
Influenza virus resistance to antiviral therapy.
@en
P2093
P1476
Influenza virus resistance to antiviral therapy.
@en
P2093
Charles Boucher
Erhard van der Vries
Martin Schutten
Pieter Fraaij
P304
P356
10.1016/B978-0-12-405880-4.00006-8
P50
P577
2013-01-01T00:00:00Z